E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Disease, where a genetic defect leads to non-functional enzyme, causing accumulation of an amino acid (phenylalanine) in the body and the presence of a related substance in urine (phenylketonuria) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10034873 |
E.1.2 | Term | Phenylketonuria (PKU) |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this trial is to evaluate the long-term neurocognitive (NC) outcomes in children with hyperphenylalaninemia (HPA) due to phenylketonuria (PKU) treated with Kuvan® and a phenylalanine (Phe)-restricted diet for 7 years. |
|
E.2.2 | Secondary objectives of the trial |
The main secondary objectives of this trial are to evaluate the growth and safety in children with HPA due to PKU treated with Kuvan® and a Phe-restricted diet and followed for a period of 7 years. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
The target population for this trial is children with confirmed diagnosis of PKU.
Inclusion criteria: • Male or female outpatients, 4 to 5 years of age (≥4 and <6) at the time of ICF signature by parent(s) or guardian(s). • Confirmed clinical and biochemical diagnosis of PKU, including at least two separate blood Phe levels ≥400 μmol/L. • Defined pre-Kuvan®/-tetrahydrobiopterin (BH4) dietary Phe tolerance consistent with the diagnosis of /PKU. • Responsive to Kuvan®/BH4: - For subjects currently treated with Kuvan®/BH4 at Screening: subject is a responder as per Investigator judgment based on documented effect of Kuvan®/BH4 on Phe levels and/or Phe tolerance. - For subjects not treated with Kuvan®/BH4 at Screening: a response test has been performed during Screening or is available from the patient’s medical records and satisfies the 3 following criteria: a decrease in blood Phe levels of at least 30% was observed after at least 24 hours with a dose of at least 10 mg/kg/day. • IQ ≥70, as assessed with the WPPSI™-III 2nd part. Note: If a subject has undertaken the same test up to 3 months before Screening as part of his/her clinical follow-up, the score can be recorded and the test doesn’t need to be repeated. • Good adherence with dietary treatment (including prescribed dietary Phe restriction and prescribed amounts of Phe-free protein supplements and low-Phe foods), as assessed by the Investigator. • Well-controlled Phe levels, as assessed by a minimum of 75% of Phe levels within the target recommended in each centre during the previous 3 months. • Low Phe diet started within the first 3 weeks of life. • Parent(s) or guardian(s) willing to comply with all study procedures, maintain strict adherence with the diet, and willing and able to provide written, signed informed consent before any trial-related activities are carried out, as well as ability of child to comply with trial procedures.
|
|
E.4 | Principal exclusion criteria |
• Known hypersensitivity to Kuvan® or its excipients. • Known hypersensitivity to other approved or non-approved formulations of tetrahydrobiopterin. • Previous diagnosis of BH4 deficiency. • Current use of methotrexate, trimethoprim or other dihydrofolate reductase inhibitors. • Current use of medications that are known to affect nitric oxide synthesis, metabolism or action. • Current use of experimental or unregistered drugs (other than sapropterin/BH4) that may affect the study outcomes or use of such agents within 30 days prior to Screening. • Concurrent use of levodopa. • Concurrent disease or condition that would induce repeatedly catabolic situations, or interfere with the trial participation, diet, or NC development, as assessed by the Investigator. • Any condition that, in the view of the Investigator, renders the subject at high risk for failure to comply with treatment or to complete the trial. • Participation in a clinical trial investigating any other agent than Kuvan® within the past 30 days.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be the mean IQ score of PKU children on diet and treated with Kuvan® after 7 years of treatment in the study. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 7 years of treatment with Kuvan® in the study. |
|
E.5.2 | Secondary end point(s) |
• Height and weight compared to the World Health Organization (WHO) Growth Standards at each time point. • Blood levels of tyrosine (Tyr), tryptophan, pre-albumin, and methylmalonic acid compared to age-related norms. • IQ score and subscores at each time-point: - the Verbal IQ, the Performance IQ and the Full Scale IQ (FSIQ) of the WPPSI™-III at baseline; - the Verbal Comprehension, the Perceptual Reasoning, the Working Memory, the Processing Speed Indexes and the FSIQ of the WISC®-IV at post-baseline time-points. • Change from baseline in FSIQ score at 2, 4 and 7 years. • Dietary Phe tolerance over the 7 year period, as represented by mean Phe prescription (in mg/day and mg/kg/day) quarterly and mean Phe intake (in mg/day) bi-annually. • Monthly Phe levels and Phe levels on the day of the IQ test. • IDC (Index of Dietary Control = half-year Phe level medians averaged from baseline to 2, 4 and 7 years). • Adherence to treatment (diet+Kuvan®) as assessed by the percentage of monthly Phe levels within target blood Phe concentration during Study Period and adherence to Kuvan® treatment as assessed by percentage of tablets taken. • Frequencies and distributions of phenylalanine hydroxylase (PAH) genotype and relationships with response to Kuvan®/BH4. • Safety (extent of exposure to Kuvan®; nature, incidence, and severity of adverse events (AEs)/serious adverse events (SAEs), including relationship to trial treatment, AEs/SAEs leading to dose modification or discontinuation of trial treatment; changes and abnormalities in vital signs and safety laboratory parameters; physical examination; use of concomitant medications).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After 7 years of treatment with Kuvan® in the study. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 18 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
This trial will be completed after: • All enrolled subjects who have received at least one dose of study drug have completed all scheduled visits or have prematurely discontinued • Follow-up of all subjects with ongoing AEs at the conclusion of treatment has been addressed • Site monitoring visits to resolve any outstanding data discrepancy issues have been completed • The database has been locked • All sites have undergone a final site closure termination visit.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 8 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 8 |